奥法妥珠单抗。
Ofatumumab.
机构信息
Harvard University, Department of Health Policy and Management, School of Public Health, Boston, MA 02115, USA.
出版信息
MAbs. 2009 Jul-Aug;1(4):326-31. doi: 10.4161/mabs.1.4.8895. Epub 2009 Jul 1.
Abstract
Ofatumumab is an anti-CD20 IgG1kappa human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia. The mAb is also being studied as a treatment for lymphoma, rheumatoid arthritis and multiple sclerosis. The candidate targets the same antigen as rituximab, but ofatumumab binds a novel, membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab. Ofatumumab might be approved in the US by August 2009.
摘要
奥法妥木单抗是一种抗 CD20 IgG1kappa 人源单克隆抗体，目前正由美国食品药品监督管理局和欧洲药品管理局考虑批准上市，用于治疗慢性淋巴细胞白血病。该药还在研究用于治疗淋巴瘤、类风湿关节炎和多发性硬化症。该候选药物的靶点与利妥昔单抗相同，但奥法妥木单抗结合的是一个新的、靠近细胞膜的表位，与利妥昔单抗相比，其从靶点解离的速度更慢。奥法妥木单抗有望于 2009 年 8 月在美国获得批准。
相似文献
1
Ofatumumab.
MAbs. 2009 Jul-Aug;1(4):326-31. doi: 10.4161/mabs.1.4.8895. Epub 2009 Jul 1.
2
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
J Clin Pharmacol. 2014 Jul;54(7):818-27. doi: 10.1002/jcph.268. Epub 2014 Jan 28.
3
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8. doi: 10.3816/CLML.2010.n.069.
4
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Oncologist. 2010;15(12):1335-43. doi: 10.1634/theoncologist.2010-0255. Epub 2010 Dec 14.
5
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Jpn J Clin Oncol. 2013 May;43(5):466-75. doi: 10.1093/jjco/hyt022. Epub 2013 Feb 28.
6
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Clin Cancer Res. 2011 Nov 1;17(21):6702-11. doi: 10.1158/1078-0432.CCR-11-0647. Epub 2011 Sep 14.
7
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
8
Ofatumumab for the treatment of chronic lymphocytic leukemia.
Expert Rev Hematol. 2015 Jun;8(3):265-72. doi: 10.1586/17474086.2015.1037736. Epub 2015 Apr 16.
9
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
J Clin Oncol. 2010 Jul 20;28(21):3525-30. doi: 10.1200/JCO.2010.27.9836. Epub 2010 May 10.
10
Ofatumumab for relapsing forms of multiple sclerosis.
Drugs Today (Barc). 2022 Jan;58(1):9-21. doi: 10.1358/dot.2022.58.1.3353168.
引用本文的文献
1
Case Report: Clinical features and management of anti-mGluR1 encephalitis: case illustration and review of the literature.
Front Integr Neurosci. 2025 Jul 23;19:1580767. doi: 10.3389/fnint.2025.1580767. eCollection 2025.
2
Anti-CD20 therapy in lupus nephritis: A revisit.
Rheumatol Immunol Res. 2025 Jul 1;6(2):66-69. doi: 10.1515/rir-2025-0009. eCollection 2025 Jun.
3
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
4
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.
Front Immunol. 2024 Dec 19;15:1476859. doi: 10.3389/fimmu.2024.1476859. eCollection 2024.
5
Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis.
Front Immunol. 2024 Nov 7;15:1456840. doi: 10.3389/fimmu.2024.1456840. eCollection 2024.
6
Cancer immunotherapies: A hope for the uncurable?
Front Mol Med. 2023 Feb 17;3:1140977. doi: 10.3389/fmmed.2023.1140977. eCollection 2023.
7
A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment.
Cureus. 2024 Apr 23;16(4):e58834. doi: 10.7759/cureus.58834. eCollection 2024 Apr.
8
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.
Nat Rev Neurol. 2024 Feb;20(2):84-98. doi: 10.1038/s41582-023-00916-w. Epub 2024 Jan 8.
9
The MR1/MAIT cell axis in CNS diseases.
Brain Behav Immun. 2024 Feb;116:321-328. doi: 10.1016/j.bbi.2023.12.029. Epub 2023 Dec 27.
10
Methods for Engineering Binders to Multi-Pass Membrane Proteins.
Bioengineering (Basel). 2023 Nov 24;10(12):1351. doi: 10.3390/bioengineering10121351.
本文引用的文献
1
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
J Immunol. 2008 Jul 1;181(1):822-32. doi: 10.4049/jimmunol.181.1.822.
2
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Blood. 2008 Jun 15;111(12):5486-95. doi: 10.1182/blood-2007-10-117671. Epub 2008 Apr 4.
3
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.
Br J Haematol. 2008 Feb;140(3):303-12. doi: 10.1111/j.1365-2141.2007.06916.x. Epub 2007 Nov 27.
4
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
Blood. 2008 Feb 1;111(3):1094-100. doi: 10.1182/blood-2007-09-111781. Epub 2007 Nov 14.
5
Role of B cells in pathogenesis of multiple sclerosis.
Int Rev Neurobiol. 2007;79:13-42. doi: 10.1016/S0074-7742(07)79002-5.
6
On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939.
APMIS. 2007 May;115(5):422-38; discussion 439. doi: 10.1111/j.1600-0463.2007.apm_682a.x.
7
The non-Hodgkin lymphomas: a review of the epidemiologic literature.
Int J Cancer. 2007;120 Suppl 12:1-39. doi: 10.1002/ijc.22719.
8
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
J Immunol. 2006 Jul 1;177(1):362-71. doi: 10.4049/jimmunol.177.1.362.
9
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
Blood. 2004 Sep 15;104(6):1793-800. doi: 10.1182/blood-2004-01-0039. Epub 2004 Jun 1.
10
Anti-CD20-based therapy of B cell lymphoma: state of the art.
Leukemia. 2002 Oct;16(10):2004-15. doi: 10.1038/sj.leu.2402639.
Zotero 插件